FDA Label for Darzalex Faspro
View Indications, Usage & Precautions
- 1 INDICATIONS AND USAGE
- 2.1 IMPORTANT DOSING INFORMATION
- 2.2 RECOMMENDED DOSAGE
- OTHER
- 2.4 DOSAGE MODIFICATIONS FOR ADVERSE REACTIONS
- 2.5 PREPARATION AND ADMINISTRATION
- 3 DOSAGE FORMS AND STRENGTHS
- 4 CONTRAINDICATIONS
- 5.1 HYPERSENSITIVITY AND OTHER ADMINISTRATION REACTIONS
- 5.2 NEUTROPENIA
- 5.3 THROMBOCYTOPENIA
- 5.4 EMBRYO-FETAL TOXICITY
- 5.5 INTERFERENCE WITH SEROLOGICAL TESTING
- 5.6 INTERFERENCE WITH DETERMINATION OF COMPLETE RESPONSE
- 6 ADVERSE REACTIONS
- 6.1 CLINICAL TRIALS EXPERIENCE
- 6.2 IMMUNOGENICITY
- 6.3 POSTMARKETING EXPERIENCE
- 8.3 FEMALES AND MALES OF REPRODUCTIVE POTENTIAL
- 8.4 PEDIATRIC USE
- 8.5 GERIATRIC USE
- 11 DESCRIPTION
- 12.1 MECHANISM OF ACTION
- 12.2 PHARMACODYNAMICS
- 12.3 PHARMACOKINETICS
- 13.1 CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY
- 15 REFERENCES
- 16 HOW SUPPLIED/STORAGE AND HANDLING
- STORAGE AND HANDLING
- 17 PATIENT COUNSELING INFORMATION
- SPL PATIENT PACKAGE INSERT
- PRINCIPAL DISPLAY PANEL - 15 ML VIAL BOX
Darzalex Faspro Product Label
The following document was submitted to the FDA by the labeler of this product Janssen Biotech, Inc.. The document includes published materials associated whith this product with the essential scientific information about this product as well as other prescribing information. Product labels may durg indications and usage, generic names, contraindications, active ingredients, strength dosage, routes of administration, appearance, warnings, inactive ingredients, etc.
1 Indications And Usage
DARZALEX FASPRO is indicated for the treatment of adult patients with multiple myeloma:
- in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant.
- in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy.
- in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy.
- as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.
2.1 Important Dosing Information
- DARZALEX FASPRO is for subcutaneous use only.
- Administer medications before and after administration of DARZALEX FASPRO to minimize administration-related reactions [see Dosage and Administration (2.3)].
- Type and screen patients prior to starting DARZALEX FASPRO.
2.2 Recommended Dosage
The recommended dose of DARZALEX FASPRO is 1,800 mg/30,000 units (1,800 mg daratumumab and 30,000 units hyaluronidase) administered subcutaneously over approximately 3–5 minutes. Tables 1, 2, and 3 provide the recommended dosing schedule when DARZALEX FASPRO is administered as monotherapy or as part of a combination therapy.
Other
Monotherapy and In Combination with Lenalidomide and Dexamethasone (D-Rd)
Use the dosing schedule provided in Table 1 when DARZALEX FASPRO is administered:
- in combination with lenalidomide and dexamethasone (4-week cycle) OR
- as monotherapy.
- Acetaminophen 650 to 1,000 mg orally
- Diphenhydramine 25 to 50 mg (or equivalent) orally or intravenously
- Corticosteroid (long- or intermediate-acting)
Monotherapy
Administer methylprednisolone 100 mg (or equivalent) orally or intravenously. Consider reducing the dose of methylprednisolone to 60 mg (or equivalent) following the second dose of DARZALEX FASPRO.
In Combination
Administer dexamethasone 20 mg (or equivalent) orally or intravenously prior to every DARZALEX FASPRO administration.
When dexamethasone is the background regimen-specific corticosteroid, the dexamethasone dose that is part of the background regimen will serve as pre-medication on DARZALEX FASPRO administration days [see Clinical Studies (14)].
Do not administer background regimen-specific corticosteroids (e.g. prednisone) on DARZALEX FASPRO administration days when patients have received dexamethasone (or equivalent) as a pre-medication.
Administer methylprednisolone 20 mg (or an equivalent dose of an intermediate- or long-acting corticosteroid) orally for 2 days starting the day after the administration of DARZALEX FASPRO.
Consider administering oral methylprednisolone at a dose of less than or equal to 20 mg (or an equivalent dose of an intermediate- or long-acting corticosteroid) beginning the day after administration of DARZALEX FASPRO.
If a background regimen-specific corticosteroid (e.g. dexamethasone, prednisone) is administered the day after the administration of DARZALEX FASPRO, additional corticosteroids may not be needed [see Clinical Studies (14)].- Remove the DARZALEX FASPRO vial from refrigerated storage [2°C to 8°C (36°F to 46°F)] and equilibrate to ambient temperature [15°C to 30°C (59°F to 86°F)]. Store the unpunctured vial at ambient temperature and ambient light for a maximum of 24 hours. Keep out of direct sunlight. Do not shake.
- Withdraw 15 mL from the vial into a syringe.
- DARZALEX FASPRO is compatible with polypropylene or polyethylene syringe material; polypropylene, polyethylene, or polyvinyl chloride (PVC) subcutaneous infusion sets; and stainless steel transfer and injection needles. Use the product immediately.
- After the solution of DARZALEX FASPRO is withdrawn into the syringe, replace the transfer needle with a syringe closing cap. Label the syringe appropriately to include the route of administration per institutional standards. Label the syringe with the peel-off label.
- To avoid needle clogging, attach the hypodermic injection needle or subcutaneous infusion set to the syringe immediately prior to injection.
- Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if opaque particles, discoloration or other foreign particles are present.
- If the syringe containing DARZALEX FASPRO is not used immediately, store the DARZALEX FASPRO solution for up to 4 hours at ambient temperature and ambient light. Discard after 4 hours, if not used.
- Inject 15 mL DARZALEX FASPRO into the subcutaneous tissue of the abdomen approximately 3 inches [7.5 cm] to the right or left of the navel over approximately 3–5 minutes. No data are available on performing the injection at other sites of the body.
- Rotate injection sites for successive injections.
- Never inject DARZALEX FASPRO into areas where the skin is red, bruised, tender, hard or areas where there are scars.
- Pause or slow down delivery rate if the patient experiences pain. In the event pain is not alleviated by pausing or slowing down delivery rate, a second injection site may be chosen on the opposite side of the abdomen to deliver the remainder of the dose.
- During treatment with DARZALEX FASPRO, do not administer other medications for subcutaneous use at the same site as DARZALEX FASPRO.
- General disorders and administration site conditions: infusion reaction, injection site reaction, chills
- Infections: herpes zoster, urinary tract infection, influenza, sepsis
- Musculoskeletal and connective tissue disorders: arthralgia, muscle spasms
- Nervous system disorders: headache, paresthesia
- Metabolism and nutrition disorders: hypocalcemia, hyperglycemia
- Respiratory, thoracic and mediastinal disorders: dyspnea, pulmonary edema
- Cardiac disorders: atrial fibrillation
- Musculoskeletal and connective tissue disorders: arthralgia, musculoskeletal chest pain
- Nervous system disorders: dizziness, headache, paresthesia
- Skin and subcutaneous tissue disorders: rash, pruritus
- Gastrointestinal disorders: abdominal pain
- Infections: influenza, sepsis, herpes zoster
- Metabolism and nutrition disorders: decreased appetite
- Cardiac disorders: atrial fibrillation
- General disorders and administration site conditions: chills, infusion reaction, injection site reaction
- Vascular disorders: hypotension, hypertension
- General disorders and administration site conditions: injection site reaction, peripheral edema
- Musculoskeletal and connective tissue disorders: arthralgia, musculoskeletal chest pain, muscle spasms
- Gastrointestinal disorders: constipation, vomiting, abdominal pain,
- Metabolism and nutrition disorders: decreased appetite, hyperglycemia, hypocalcemia, dehydration
- Psychiatric disorders: insomnia
- Vascular disorders: hypertension, hypotension
- Nervous system disorders: dizziness, peripheral sensory neuropathy, paresthesia
- Infections: bronchitis, influenza, urinary tract infection, herpes zoster, sepsis, hepatitis B reactivation
- Skin and subcutaneous tissue disorders: pruritus, rash
- Cardiac disorders: atrial fibrillation
- Respiratory, thoracic and mediastinal disorders: pulmonary edema
Weeks | Schedule |
---|---|
Weeks 1 to 8 | weekly (total of 8 doses) |
Weeks 9 to 24 First dose of the every-2-week dosing schedule is given at Week 9 | every two weeks (total of 8 doses) |
Week 25 onwards until disease progression First dose of the every-4-week dosing schedule is given at Week 25 | every four weeks |
When DARZALEX FASPRO is administered as part of a combination therapy, see Clinical Studies (14.2) and the prescribing information for dosage recommendations for the other drugs.
In Combination with Bortezomib, Melphalan and Prednisone (D-VMP)
Use the dosing schedule provided in Table 2 when DARZALEX FASPRO is administered in combination with bortezomib, melphalan and prednisone (6-week cycle).
Weeks | Schedule |
---|---|
Weeks 1 to 6 | weekly (total of 6 doses) |
Weeks 7 to 54 First dose of the every-3-week dosing schedule is given at Week 7 | every three weeks (total of 16 doses) |
Week 55 onwards until disease progression First dose of the every-4-week dosing schedule is given at Week 55 | every four weeks |
When DARZALEX FASPRO is administered as part of a combination therapy, see Clinical Studies (14.1) and the prescribing information for dosage recommendations for the other drugs.
In Combination with Bortezomib and Dexamethasone (D-Vd)
Use the dosing schedule in Table 3 when DARZALEX FASPRO is administered in combination with bortezomib and dexamethasone (3-week cycle).
Weeks | Schedule |
---|---|
Weeks 1 to 9 | weekly (total of 9 doses) |
Weeks 10 to 24 First dose of the every-3-week dosing schedule is given at Week 10 | every three weeks (total of 5 doses) |
Week 25 onwards until disease progression First dose of the every-4-week dosing schedule is given at Week 25 | every four weeks |
When DARZALEX FASPRO is administered as part of a combination therapy, see the prescribing information for dosage recommendations for the other drugs.
Missed DARZALEX FASPRO Doses
If a dose of DARZALEX FASPRO is missed, administer the dose as soon as possible and adjust the dosing schedule to maintain the dosing interval.
Pre-medication
Administer the following pre-medications 1–3 hours before each dose of DARZALEX FASPRO:
Post-medication
Administer the following post-medications:
If the patient does not experience a major systemic administration-related reaction after the first 3 doses of DARZALEX FASPRO, consider discontinuing the administration of corticosteroids (excluding any background regimen-specific corticosteroid).
For patients with a history of chronic obstructive pulmonary disease, consider prescribing short and long-acting bronchodilators and inhaled corticosteroids. Following the first 4 doses of DARZALEX FASPRO, consider discontinuing these additional post-medications, if the patient does not experience a major systemic administration-related reaction.
Prophylaxis for Herpes Zoster Reactivation
Initiate antiviral prophylaxis to prevent herpes zoster reactivation within 1 week after starting DARZALEX FASPRO and continue for 3 months following the end of treatment [see Adverse Reactions (6.1)].
Preparation
Storage
Administration
Systemic Reactions
In a pooled safety population of 490 patients who received DARZALEX FASPRO as monotherapy or in combination, 11% of patients experienced a systemic administration-related reaction (Grade 2: 3.9%, Grade 3: 1.4%). Systemic administration-related reactions occurred in 10% of patients with the first injection, 0.2% with the second injection, and cumulatively 0.8% with subsequent injections. The median time to onset was 3.7 hours (range: 9 minutes to 3.5 days). Of the 84 systemic administration-related reactions that occurred in 52 patients, 73 (87%) occurred on the day of DARZALEX FASPRO administration. Delayed systemic administration-related reactions have occurred in less than 1% of the patients.
Severe reactions included hypoxia, dyspnea, hypertension and tachycardia. Other signs and symptoms of systemic administration-related reactions may include respiratory symptoms, such as bronchospasm, nasal congestion, cough, throat irritation, allergic rhinitis, and wheezing, as well as anaphylactic reaction, pyrexia, chest pain, pruritis, chills, vomiting, nausea, and hypotension.
Pre-medicate patients with histamine-1 receptor antagonist, acetaminophen and corticosteroids [see Dosage and Administration (2.3)]. Monitor patients for systemic administration-related reactions, especially following the first and second injections. For anaphylactic reaction or life-threatening (Grade 4) administration-related reactions, immediately and permanently discontinue DARZALEX FASPRO. Consider administering corticosteroids and other medications after the administration of DARZALEX FASPRO depending on dosing regimen and medical history to minimize the risk of delayed (defined as occurring the day after administration) systemic administration-related reactions [see Dosage and Administration (2.3)].
Local Reactions
In this pooled safety population, injection-site reactions occurred in 8% of patients, including Grade 2 reactions in 0.6%. The most frequent (>1%) injection-site reaction was injection site erythema. These local reactions occurred a median of 7 minutes (range: 0 minutes to 4.7 days) after starting administration of DARZALEX FASPRO. Monitor for local reactions and consider symptomatic management.
Newly Diagnosed Multiple Myeloma
In Combination with Bortezomib, Melphalan and Prednisone
The safety of DARZALEX FASPRO with bortezomib, melphalan and prednisone (D-VMP) was evaluated in a single-arm cohort of PLEIADES [see Clinical Studies (14.1)]. Patients received DARZALEX FASPRO 1,800 mg/30,000 units administered subcutaneously once weekly from weeks 1 to 6, once every 3 weeks from weeks 7 to 54 and once every 4 weeks starting with week 55 until disease progression or unacceptable toxicity (N=67) in combination with bortezomib, melphalan and prednisone. Among these patients, 93% were exposed for 6 months or longer and 19% were exposed for greater than one year.
Serious adverse reactions occurred in 39% of patients who received DARZALEX FASPRO. Serious adverse reactions in >5% of patients included pneumonia and pyrexia. Fatal adverse reactions occurred in 3.0% of patients.
Permanent discontinuation of DARZALEX FASPRO due to an adverse reaction occurred in 4.5% of patients. The adverse reaction resulting in permanent discontinuation of DARZALEX FASPRO in more than 1 patient was neutropenic sepsis.
Dosage interruptions (defined as dose delays or skipped doses) due to an adverse reaction occurred in 51% of patients who received DARZALEX FASPRO. Adverse reactions requiring dosage interruptions in >5% of patients included thrombocytopenia, neutropenia, anemia, and pneumonia.
The most common adverse reactions (≥20%) were upper respiratory tract infection, constipation, nausea, fatigue, pyrexia, peripheral sensory neuropathy, diarrhea, cough, insomnia, vomiting, and back pain.
Table 4 summarizes the adverse reactions in patients who received DARZALEX FASPRO with bortezomib, melphalan and prednisone (D-VMP) in PLEIADES.
Adverse Reaction | DARZALEX FASPRO with Bortezomib, Melphalan and Prednisone (N=67) | |
---|---|---|
All Grades (%) | Grades ≥3 (%) | |
Infections | ||
Upper respiratory tract infection Upper respiratory tract infection includes nasopharyngitis, respiratory syncytial virus infection, respiratory tract infection, rhinitis, tonsillitis, upper respiratory tract infection, and viral pharyngitis. | 39 | 0 |
Bronchitis | 16 | 0 |
Pneumonia Pneumonia includes lower respiratory tract infection, lung infection, pneumocystis jirovecii pneumonia, pneumonia, and pneumonia bacterial. | 15 | 7 Only grade 3 adverse reactions occurred. |
Gastrointestinal disorders | ||
Constipation | 37 | 0 |
Nausea | 36 | 0 |
Diarrhea | 33 | 3 |
Vomiting | 21 | 0 |
Abdominal pain Abdominal pain includes abdominal pain, and abdominal pain upper. | 13 | 0 |
General disorders and administration site conditions | ||
Fatigue Fatigue includes asthenia, and fatigue. | 36 | 3 |
Pyrexia | 34 | 0 |
Edema peripheral Edema peripheral includes edema, edema peripheral, and peripheral swelling. | 13 | 1 |
Nervous system disorders | ||
Peripheral sensory neuropathy | 34 | 1 |
Dizziness | 10 | 0 |
Respiratory, thoracic and mediastinal disorders | ||
Cough Cough includes cough, and productive cough. | 24 | 0 |
Psychiatric disorders | ||
Insomnia | 22 | 3 |
Musculoskeletal and connective tissue disorders | ||
Back pain | 21 | 3 |
Musculoskeletal chest pain | 12 | 0 |
Metabolism and nutrition disorders | ||
Decreased appetite | 15 | 1 |
Skin and subcutaneous tissue disorders | ||
Rash | 13 | 0 |
Pruritus | 12 | 0 |
Vascular disorders | ||
Hypertension | 13 | 6 |
Hypotension | 10 | 3 |
Clinically relevant adverse reactions in <10% of patients who received DARZALEX FASPRO with bortezomib, melphalan and prednisone (D-VMP) include:
Table 5 summarizes the laboratory abnormalities in patients who received DARZALEX FASPRO with bortezomib, melphalan and prednisone (D-VMP) in PLEIADES.
Laboratory Abnormality | DARZALEX FASPRO with Bortezomib, Melphalan and Prednisone Denominator is based on the safety population treated with D-VMP (N=67). | |
---|---|---|
All Grades (%) | Grades 3–4 (%) | |
Decreased leukocytes | 96 | 52 |
Decreased lymphocytes | 93 | 84 |
Decreased platelets | 93 | 42 |
Decreased neutrophils | 88 | 49 |
Decreased hemoglobin | 48 | 19 |
Relapsed/Refractory Multiple Myeloma
In Combination with Lenalidomide and Dexamethasone
The safety of DARZALEX FASPRO with lenalidomide and dexamethasone (D-Rd) was evaluated in a single-arm cohort of PLEIADES [see Clinical Studies (14.2)]. Patients received DARZALEX FASPRO 1,800 mg/30,000 units administered subcutaneously once weekly from weeks 1 to 8, once every 2 weeks from weeks 9 to 24 and once every 4 weeks starting with week 25 until disease progression or unacceptable toxicity (N=65) in combination with lenalidomide and dexamethasone. Among these patients, 92% were exposed for 6 months or longer and 20% were exposed for greater than one year.
Serious adverse reactions occurred in 48% of patients who received DARZALEX FASPRO. Serious adverse reactions in >5% of patients included pneumonia, influenza and diarrhea. Fatal adverse reactions occurred in 3.1% of patients.
Permanent discontinuation of DARZALEX FASPRO due to an adverse reaction occurred in 11% of patients who received DARZALEX FASPRO. Adverse reactions resulting in permanent discontinuation of DARZALEX FASPRO in more than 1 patient were pneumonia and anemia.
Dosage interruptions due to an adverse reaction occurred in 63% of patients who received DARZALEX FASPRO. Adverse reactions requiring dosage interruptions in >5% of patients included neutropenia, pneumonia, upper respiratory tract infection, influenza, dyspnea, and blood creatinine increased.
The most common adverse reactions (≥20%) were fatigue, diarrhea, upper respiratory tract infection, muscle spasms, constipation, pyrexia, pneumonia, and dyspnea.
Table 6 summarizes the adverse reactions in patients who received DARZALEX FASPRO with lenalidomide and dexamethasone (D-Rd) in PLEIADES.
Adverse Reaction | DARZALEX FASPRO with Lenalidomide and Dexamethasone (N=65) | |
---|---|---|
All Grades (%) | Grades ≥3 (%) | |
General disorders and administration site conditions | ||
Fatigue Fatigue includes asthenia, and fatigue. | 52 | 5 Only grade 3 adverse reactions occurred. |
Pyrexia | 23 | 2 |
Edema peripheral | 18 | 3 |
Gastrointestinal disorders | ||
Diarrhea | 45 | 5 |
Constipation | 26 | 2 |
Nausea | 12 | 0 |
Vomiting | 11 | 0 |
Infections | ||
Upper respiratory tract infection Upper respiratory tract infection includes nasopharyngitis, pharyngitis, respiratory tract infection viral, rhinitis, sinusitis, upper respiratory tract infection, and upper respiratory tract infection bacterial. | 43 | 3 |
Pneumonia Pneumonia includes lower respiratory tract infection, lung infection, and pneumonia. | 23 | 17 |
Bronchitis Bronchitis includes bronchitis, and bronchitis viral. | 14 | 2 |
Urinary tract infection | 11 | 0 |
Musculoskeletal and connective tissue disorders | ||
Muscle spasms | 31 | 2 |
Back pain | 14 | 0 |
Respiratory, thoracic and mediastinal disorders | ||
Dyspnea Dyspnea includes dyspnea, and dyspnea exertional. | 22 | 3 |
Cough Cough includes cough, and productive cough. | 14 | 0 |
Nervous system disorders | ||
Peripheral sensory neuropathy | 17 | 2 |
Psychiatric disorders | ||
Insomnia | 17 | 5 |
Metabolism and nutrition disorders | ||
Hyperglycemia | 12 | 9 |
Hypocalcemia | 11 | 0 |
Clinically relevant adverse reactions in <10% of patients who received DARZALEX FASPRO with lenalidomide and dexamethasone (D-Rd) include:
Table 7 summarizes the laboratory abnormalities in patients who received DARZALEX FASPRO with lenalidomide and dexamethasone (D-Rd) in PLEIADES.
Laboratory Abnormality | DARZALEX FASPRO with Lenalidomide and Dexamethasone Denominator is based on the safety population treated with D-Rd (N=65). | |
---|---|---|
All Grades (%) | Grades 3–4 (%) | |
Decreased leukocytes | 94 | 34 |
Decreased lymphocytes | 82 | 58 |
Decreased platelets | 86 | 9 |
Decreased neutrophils | 89 | 52 |
Decreased hemoglobin | 45 | 8 |
Monotherapy
The safety of DARZALEX FASPRO as monotherapy was evaluated in COLUMBA [see Clinical Trials (14.2)]. Patients received DARZALEX FASPRO 1,800 mg/30,000 units administered subcutaneously or daratumumab 16 mg/kg administered intravenously; each administered once weekly from weeks 1 to 8, once every 2 weeks from weeks 9 to 24 and once every 4 weeks starting with week 25 until disease progression or unacceptable toxicity. Among patients receiving DARZALEX FASPRO, 37% were exposed for 6 months or longer and 1% were exposed for greater than one year.
Serious adverse reactions occurred in 26% of patients who received DARZALEX FASPRO. Fatal adverse reactions occurred in 5% of patients. Fatal adverse reactions occurring in more than 1 patient were general physical health deterioration, septic shock, and respiratory failure.
Permanent discontinuation due to an adverse reaction occurred in 10% of patients who received DARZALEX FASPRO. Adverse reactions resulting in permanent discontinuation of DARZALEX FASPRO in more than 2 patients were thrombocytopenia and hypercalcemia.
Dosage interruptions due to an adverse reaction occurred in 26% of patients who received DARZALEX FASPRO. Adverse reactions requiring dosage interruption in >5% of patients included thrombocytopenia.
The most common adverse reaction (≥20%) was upper respiratory tract infection.
Table 8 summarizes the adverse reactions in COLUMBA.
Adverse Reaction | DARZALEX FASPRO (N=260) | Intravenous Daratumumab (N=258) | ||
---|---|---|---|---|
All Grades (%) | Grade ≥3 (%) | All Grades (%) | Grade ≥3 (%) | |
Infections | ||||
Upper respiratory tract infection Upper respiratory tract infection includes acute sinusitis, nasopharyngitis, pharyngitis, respiratory syncytial virus infection, respiratory tract infection, rhinitis, rhinovirus infection, sinusitis, and upper respiratory tract infection. | 24 | 1 Only grade 3 adverse reactions occurred. | 22 | 1 |
Pneumonia Pneumonia includes lower respiratory tract infection, lung infection, pneumocystis jirovecii pneumonia, and pneumonia. | 8 | 5 | 10 | 6 Grade 5 adverse reactions occurred. |
Gastrointestinal disorders | ||||
Diarrhea | 15 | 1 | 11 | 0.4 |
Nausea | 8 | 0.4 | 11 | 0.4 |
General disorders and administration site conditions | ||||
Fatigue Fatigue includes asthenia, and fatigue. | 15 | 1 | 16 | 2 |
Infusion reactions Infusion reactions includes terms determined by investigators to be related to infusion. | 13 | 2 | 34 | 5 |
Pyrexia | 13 | 0 | 13 | 1 |
Chills | 6 | 0.4 | 12 | 1 |
Musculoskeletal and connective tissue disorders | ||||
Back pain | 10 | 2 | 12 | 3 |
Respiratory, thoracic and mediastinal disorders | ||||
Cough Cough includes cough, and productive cough. | 9 | 1 | 14 | 0 |
Dyspnea Dyspnea includes dyspnea, and dyspnea exertional. | 6 | 1 | 11 | 1 |
Clinically relevant adverse reactions in <10% of patients who received DARZALEX FASPRO include:
Table 9 summarizes the laboratory abnormalities in COLUMBA.
Laboratory Abnormality | DARZALEX FASPRO Denominator is based on the safety population treated with DARZALEX FASPRO (N=260) and Intravenous Daratumumab (N=258). | Intravenous Daratumumab | ||
---|---|---|---|---|
All Grades (%) | Grades 3–4 (%) | All Grades (%) | Grades 3–4 (%) | |
Decreased leukocytes | 65 | 19 | 57 | 14 |
Decreased lymphocytes | 59 | 36 | 56 | 36 |
Decreased neutrophils | 55 | 19 | 43 | 11 |
Decreased platelets | 43 | 16 | 45 | 14 |
Decreased hemoglobin | 42 | 14 | 39 | 16 |
Interference with Indirect Antiglobulin Tests (Indirect Coombs Test)
Daratumumab binds to CD38 on RBCs and interferes with compatibility testing, including antibody screening and cross matching. Daratumumab interference mitigation methods include treating reagent RBCs with dithiothreitol (DTT) to disrupt daratumumab binding [see References (15)] or genotyping. Since the Kell blood group system is also sensitive to DTT treatment, supply K-negative units after ruling out or identifying alloantibodies using DTT-treated RBCs.
If an emergency transfusion is required, administer non-cross-matched ABO/RhD-compatible RBCs per local blood bank practices.
Interference with Serum Protein Electrophoresis and Immunofixation Tests
Daratumumab may be detected on serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for monitoring disease monoclonal immunoglobulins (M protein). False positive SPE and IFE assay results may occur for patients with IgG kappa myeloma protein impacting initial assessment of complete responses by International Myeloma Working Group (IMWG) criteria. In DARZALEX FASPRO-treated patients with persistent very good partial response, where daratumumab interference is suspected, consider using a FDA-approved daratumumab-specific IFE assay to distinguish daratumumab from any remaining endogenous M protein in the patient's serum, to facilitate determination of a complete response.
Risk Summary
DARZALEX FASPRO can cause fetal harm when administered to a pregnant woman. The assessment of associated risks with daratumumab products is based on the mechanism of action and data from target antigen CD38 knockout animal models (see Data). There are no available data on the use of DARZALEX FASPRO in pregnant women to evaluate drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted.
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
The combination of DARZALEX FASPRO and lenalidomide is contraindicated in pregnant women, because lenalidomide may cause birth defects and death of the unborn child. Lenalidomide is only available through a REMS program. Refer to the lenalidomide prescribing information on use during pregnancy.
Clinical Considerations
Fetal/Neonatal Adverse Reactions
Immunoglobulin G1 (IgG1) monoclonal antibodies are transferred across the placenta. Based on its mechanism of action, DARZALEX FASPRO may cause depletion of fetal CD38 positive immune cells and decreased bone density. Defer administering live vaccines to neonates and infants exposed to daratumumab in utero until a hematology evaluation is completed.
Data
Animal Data
DARZALEX FASPRO for subcutaneous injection contains daratumumab and hyaluronidase. Mice that were genetically modified to eliminate all CD38 expression (CD38 knockout mice) had reduced bone density at birth that recovered by 5 months of age. Data from studies using CD38 knockout animal models also suggest the involvement of CD38 in the regulation of humoral immune responses (mice), feto-maternal immune tolerance (mice), and early embryonic development (frogs).
No systemic exposure of hyaluronidase was detected in monkeys given 22,000 U/kg subcutaneously (12 times higher than the human dose) and there were no effects on embryo-fetal development in pregnant mice given 330,000 U/kg hyaluronidase subcutaneously daily during organogenesis, which is 45 times higher than the human dose.
There were no effects on pre- and post-natal development through sexual maturity in offspring of mice treated daily from implantation through lactation with 990,000 U/kg hyaluronidase subcutaneously, which is 134 times higher than the human doses.
Risk Summary
There is no data on the presence of daratumumab and hyaluronidase in human milk, the effects on the breastfed child, or the effects on milk production. Maternal immunoglobulin G is known to be present in human milk. Published data suggest that antibodies in breast milk do not enter the neonatal and infant circulations in substantial amounts. Because of the potential for serious adverse reactions in the breastfed child when DARZALEX FASPRO is administered with lenalidomide and dexamethasone, advise women not to breastfeed during treatment with DARZALEX FASPRO. Refer to lenalidomide prescribing information for additional information.
Data
Animal Data
No systemic exposure of hyaluronidase was detected in monkeys given 22,000 U/kg subcutaneously (12 times higher than the human dose) and there were no effects on post-natal development through sexual maturity in offspring of mice treated daily during lactation with 990,000 U/kg hyaluronidase subcutaneously, which is 134 times higher than the human doses.
Pregnancy Testing
With the combination of DARZALEX FASPRO with lenalidomide, refer to the lenalidomide labeling for pregnancy testing requirements prior to initiating treatment in females of reproductive potential.
Contraception
Advise females of reproductive potential to use effective contraception during treatment with DARZALEX FASPRO and for 3 months after the last dose. Additionally, refer to the lenalidomide labeling for additional recommendations for contraception.
Cardiac Electrophysiology
DARZALEX FASPRO as a large protein has a low likelihood of direct ion channel interactions. There is no evidence from non-clinical or clinical data to suggest that DARZALEX FASPRO has the potential to delay ventricular repolarization.
Exposure-Response Relationship
The exposure-response relationship and time course of pharmacodynamics of DARZALEX FASPRO have not been fully characterized.
Absorption
At the recommended dose of DARZALEX FASPRO 1,800 mg/30,000 units, the absolute bioavailability is 69%, with peak concentrations occurring around 3 days (Tmax).
Distribution
The estimated mean (coefficient of variation, CV) volume of distribution for the central compartment is 5.2 L (37%) and peripheral compartment was 3.8 L.
Elimination
Daratumumab is cleared by parallel linear and nonlinear saturable target mediated clearances. The estimated mean (CV%) linear clearance of daratumumab is 119 mL/day. The estimated mean (CV%) elimination half-life associated with linear clearance is 20 days (22%).
Specific Populations
The following population characteristics have no clinically meaningful effect on the pharmacokinetics of daratumumab in patients administered DARZALEX FASPRO as monotherapy or as combination therapy: sex, age (33 to 92 years), race, renal impairment [Creatinine clearance (CLcr) 15 to 89 mL/min as determined by the Cockcroft-Gault formula], and mild hepatic impairment (total bilirubin 1 to 1.5 times ULN and AST>ULN). The effect of moderate and severe hepatic impairment on daratumumab pharmacokinetics is unknown.
Body Weight
After administration of DARZALEX FASPRO 1,800 mg/30,000 units as monotherapy, the mean maximum Ctrough after the 8th dose was 12% lower in the higher body weight (BW) group (>85 kg) while the mean maximum Ctrough was 81% higher in the lower BW group (≤50 kg) compared to the corresponding BW groups in the intravenous daratumumab arm.
In Combination with Bortezomib, Melphalan and Prednisone
The efficacy of DARZALEX FASPRO with bortezomib, melphalan and prednisone (D-VMP) was evaluated in a single-arm cohort of PLEIADES (NCT03412565), a multi-cohort, open-label trial. Eligible patients were required to have newly diagnosed multiple myeloma who are ineligible for transplant. Patients received DARZALEX FASPRO 1,800 mg/30,000 units administered subcutaneously once weekly from weeks 1 to 6, once every 3 weeks from weeks 7 to 54 and once every 4 weeks starting with week 55 until disease progression or unacceptable toxicity; bortezomib 1.3 mg/m2 subcutaneously twice weekly on Weeks 1, 2, 4 and 5 for the first 6-week cycle (Cycle 1; 8 doses), followed by once weekly on Weeks 1, 2, 4 and 5 for eight more 6-week cycles (Cycles 2–9; 4 doses per cycle); and melphalan 9 mg/m2 and prednisone 60 mg/m2 orally on Days 1 to 4 of the nine 6-week cycles (Cycles 1–9). The major efficacy outcome measure was overall response rate (ORR).
A total of 67 patients received DARZALEX FASPRO with VMP. The median age was 75 years (range: 66 to 86); 46% were male; 69% were White, 8% Asian, and 2% Black or African American; and 33% had ISS Stage I, 45% had ISS Stage II, and 22% had ISS Stage III disease.
Efficacy results are summarized in Table 10
D-VMP (N=67) | |
---|---|
CI=confidence interval | |
Overall response rate (sCR+CR+VGPR+PR), n (%) Based on treated patients | 59 (88%) |
95% CI (%) | (78%, 95%) |
Stringent complete response (sCR) | 5 (8%) |
Complete response (CR) | 7 (10%) |
Very good partial response (VGPR) | 31 (46%) |
Partial response (PR) | 16 (24%) |
In Combination with Lenalidomide and Dexamethasone
The efficacy of DARZALEX FASPRO with lenalidomide and dexamethasone (D-Rd) was evaluated in a single-arm cohort of PLEIADES (NCT03412565), a multi-cohort, open-label trial. Patients received DARZALEX FASPRO 1,800 mg/30,000 units administered subcutaneously once weekly from weeks 1 to 8, once every 2 weeks from weeks 9 to 24 and once every 4 weeks starting with week 25 until disease progression or unacceptable toxicity with lenalidomide 25 mg once daily orally on Days 1–21 of each 28-day cycle; and dexamethasone 40 mg per week (or a reduced dose of 20 mg per week for patients >75 years or BMI <18.5). The major efficacy outcome measure was ORR.
A total of 65 patients received DARZALEX FASPRO with Rd. The median age was 69 years (range: 33 to 82); 69% were male; 69% were White, and 3% Black or African American; and 42% had ISS Stage I, 30% had ISS Stage II, and 28% had ISS Stage III disease. Patients had received a median of 1 prior line of therapy. A total of 52% of patients had a prior ASCT; 95% of patients received a prior PI; 59% received a prior immunomodulatory agent, including 22% who received prior lenalidomide; and 54% of patients received both a prior PI and immunomodulatory agent.
Efficacy results are summarized in Table 11.
D-Rd (N=65) | |
---|---|
CI=confidence interval | |
Overall response rate (sCR+CR+VGPR+PR), n (%) Based on treated patients | 59 (91%) |
95% CI (%) | (81%, 97%) |
Stringent complete response (sCR) | 4 (6%) |
Complete response (CR) | 8 (12%) |
Very good partial response (VGPR) | 30 (46%) |
Partial response (PR) | 17 (26%) |
Monotherapy
The efficacy of DARZALEX FASPRO as monotherapy was evaluated in COLUMBA (NCT03277105), an open-label, randomized, non-inferiority study. Eligible patients were required to have relapsed or refractory multiple myeloma who had received at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or who were double-refractory to a proteasome inhibitor and an immunomodulatory agent. Patients were randomized to receive DARZALEX FASPRO (1,800 mg/30,000 units) administered subcutaneously or daratumumab 16 mg/kg administered intravenously; each administered once weekly from weeks 1 to 8, once every 2 weeks from weeks 9 to 24 and once every 4 weeks starting with week 25 until unacceptable toxicity or disease progression. The major efficacy outcome measures were ORR by the IMWG response criteria and maximum Ctrough at pre-dose Cycle 3 Day 1 [see Clinical Pharmacology (12.3)]. Randomization was stratified by body weight, myeloma type, and number of prior lines of therapy.
A total of 522 patients were randomized: 263 to the DARZALEX FASPRO arm and 259 to the intravenous daratumumab arm. The median age was 67 years (range: 33 to 92); 55% were male; and 78% were White, 14% Asian, and 3% Black or African American. The median weight was 73 kg (range: 29 to 138). Patients had received a median of 4 prior lines of therapy. A total of 51% of patients had a prior ASCT; 100% of patients received both a PI and an immunomodulatory agent. Forty-nine percent of patients were refractory both a PI and an immunomodulatory agent. Eighty-two percent of patients were refractory to their last line of prior systemic therapy.
The results show that DARZALEX FASPRO 1,800 mg/30,000 units administered subcutaneously is non-inferior to daratumumab 16 mg/kg administered intravenously in terms of ORR and maximum trough concentration [see Clinical Pharmacology (12.3)]. Median progression-free survival was 5.6 months in the DARZALEX FASPRO arm and 6.1 months in the intravenous daratumumab arm. ORR results are provided in Table 12.
DARZALEX FASPRO (N=263) | Intravenous Daratumumab (N=259) | |
---|---|---|
Overall response (sCR+CR+VGPR+PR), n (%) Based on intent-to-treat population. | 108 (41%) | 96 (37%) |
95% CI (%) | (35%, 47%) | (31%, 43%) |
Ratio of response rates (95% CI)b | 1.11 (0.89, 1.37) | |
CR or better, n (%) | 5 (1.9%) | 7 (2.7%) |
Very good partial response (VGPR) | 45 (17%) | 37 (14%) |
Partial response (PR) | 58 (22%) | 52 (20%) |
Hypersensitivity and Other Administration Reactions
Advise patients to seek immediate medical attention for any of the following signs and symptoms of systemic administration-related reactions: itchy, runny or blocked nose; chills, nausea, throat irritation, cough, headache, shortness of breath or difficulty breathing [see Warnings and Precautions (5.1)].
Neutropenia
Advise patients to contact their healthcare provider if they have a fever [see Warnings and Precautions (5.2)].
Thrombocytopenia
Advise patients to contact their healthcare provider if they have bruising or bleeding [see Warnings and Precautions (5.3)].
Embryo-Fetal Toxicity
Advise pregnant women of the potential hazard to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions (5.4), Use in Specific Populations (8.1, 8.3)].
Advise females of reproductive potential to avoid becoming pregnant during treatment with DARZALEX FASPRO and for at least 3 months after the last dose [see Use in Specific Populations (8.1, 8.3)].
Advise patients that lenalidomide has the potential to cause fetal harm and has specific requirements regarding contraception, pregnancy testing, blood and sperm donation, and transmission in sperm. Lenalidomide is only available through a REMS program [see Use in Specific Populations (8.1, 8.3)].
Interference with Laboratory Tests
Advise patients to inform their healthcare provider, including personnel at blood transfusion centers, that they are taking DARZALEX FASPRO, in the event of a planned transfusion [see Warnings and Precautions (5.5)].
Advise patients that DARZALEX FASPRO can affect the results of some tests used to determine complete response in some patients and additional tests may be needed to evaluate response [see Warnings and Precautions (5.6)].
Hepatitis B Virus (HBV) Reactivation
Advise patients to inform healthcare providers if they have ever had or might have a hepatitis B infection and that DARZALEX FASPRO could cause hepatitis B virus to become active again [see Adverse Reactions (6.1)].
Product of Switzerland
Manufactured by:
Janssen Biotech, Inc.
Horsham, PA 19044
U.S. License Number 1864
© 2020 Janssen Pharmaceutical Companies
2.4 Dosage Modifications For Adverse Reactions
No dose reductions of DARZALEX FASPRO are recommended. Consider withholding DARZALEX FASPRO to allow recovery of blood cell counts in the event of myelosuppression [see Warnings and Precautions (5.2, 5.3)].
2.5 Preparation And Administration
DARZALEX FASPRO should be administered by a healthcare provider.
To prevent medication errors, check the vial labels to ensure that the drug being prepared and administered is DARZALEX FASPRO for subcutaneous use. Do not administer DARZALEX FASPRO intravenously.
DARZALEX FASPRO is ready to use.
3 Dosage Forms And Strengths
Injection: 1,800 mg daratumumab and 30,000 units hyaluronidase per 15 mL (120 mg and 2,000 units/mL) colorless to yellow and clear to opalescent solution in a single-dose vial.
4 Contraindications
DARZALEX FASPRO is contraindicated in patients with a history of severe hypersensitivity to daratumumab, hyaluronidase or any of the components of the formulation [see Warnings and Precautions (5.1) and Adverse Reactions (6.3)].
5.1 Hypersensitivity And Other Administration Reactions
Both systemic administration-related reactions, including severe or life-threatening reactions, and local injection-site reactions can occur with DARZALEX FASPRO.
5.2 Neutropenia
Daratumumab may increase neutropenia induced by background therapy [see Adverse Reactions (6.1)].
Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Monitor patients with neutropenia for signs of infection. Consider withholding DARZALEX FASPRO until recovery of neutrophils. In lower body weight patients receiving DARZALEX FASPRO, higher rates of Grade 3–4 neutropenia were observed.
5.3 Thrombocytopenia
Daratumumab may increase thrombocytopenia induced by background therapy [see Adverse Reactions (6.1)].
Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Consider withholding DARZALEX FASPRO until recovery of platelets.
5.4 Embryo-Fetal Toxicity
Based on the mechanism of action, DARZALEX FASPRO can cause fetal harm when administered to a pregnant woman. DARZALEX FASPRO may cause depletion of fetal immune cells and decreased bone density. Advise pregnant women of the potential risk to a fetus. Advise females with reproductive potential to use effective contraception during treatment with DARZALEX FASPRO and for 3 months after the last dose [see Use in Specific Populations (8.1, 8.3)].
The combination of DARZALEX FASPRO with lenalidomide is contraindicated in pregnant women, because lenalidomide may cause birth defects and death of the unborn child. Refer to the lenalidomide prescribing information on use during pregnancy.
5.5 Interference With Serological Testing
Daratumumab binds to CD38 on red blood cells (RBCs) and results in a positive Indirect Antiglobulin Test (Indirect Coombs test). Daratumumab-mediated positive indirect antiglobulin test may persist for up to 6 months after the last daratumumab administration. Daratumumab bound to RBCs masks detection of antibodies to minor antigens in the patient's serum [see References (15)]. The determination of a patient's ABO and Rh blood type are not impacted [see Drug Interactions (7.1)].
Notify blood transfusion centers of this interference with serological testing and inform blood banks that a patient has received DARZALEX FASPRO. Type and screen patients prior to starting DARZALEX FASPRO [see Dosage and Administration (2.1)].
5.6 Interference With Determination Of Complete Response
Daratumumab is a human IgG kappa monoclonal antibody that can be detected on both the serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for the clinical monitoring of endogenous M-protein [see Drug Interactions (7.1)]. This interference can impact the determination of complete response and of disease progression in some DARZALEX FASPRO-treated patients with IgG kappa myeloma protein.
6 Adverse Reactions
The following clinically significant adverse reactions are described elsewhere in the labeling:
- Hypersensitivity and Other Administration Reactions [see Warning and Precautions (5.1)].
- Neutropenia [see Warning and Precautions (5.2)].
- Thrombocytopenia [see Warning and Precautions (5.3)].
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
6.2 Immunogenicity
As with all therapeutic proteins, there is the potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other daratumumab products or other hyaluronidase products may be misleading.
Treatment-emergent anti-daratumumab antibodies were tested in 451 patients treated with DARZALEX FASPRO as monotherapy or as part of a combination therapy. One patient (0.2%) who received DARZALEX FASPRO as monotherapy tested positive for anti-daratumumab antibodies and transient neutralizing antibodies. However, the incidence of antibody development might not have been reliably determined because the assays that were used have limitations in detecting anti-daratumumab antibodies in the presence of high concentrations of daratumumab.
Treatment-emergent anti-rHuPH20 antibodies developed in 8% (19/255) of patients who received DARZALEX FASPRO as monotherapy and in 8% (16/192) of patients who received DARZALEX FASPRO as part of a combination therapy. The anti-rHuPH20 antibodies did not appear to affect daratumumab exposures. None of the patients who tested positive for anti-rHuPH20 antibodies tested positive for neutralizing antibodies.
6.3 Postmarketing Experience
The following adverse reactions have been identified with use of intravenous daratumumab. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Immune System: Anaphylactic reaction
Gastrointestinal: Pancreatitis
8.3 Females And Males Of Reproductive Potential
DARZALEX FASPRO can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)].
8.4 Pediatric Use
Safety and effectiveness of DARZALEX FASPRO in pediatric patients have not been established.
8.5 Geriatric Use
Of the 291 patients who received DARZALEX FASPRO as monotherapy for relapsed and refractory multiple myeloma, 37% were 65 to <75 years of age, and 19% were 75 years of age or older. No overall differences in effectiveness were observed based on age. Adverse reactions occurring at a higher frequency (≥5% difference) in patients ≥65 years of age included upper respiratory tract infection, urinary tract infection, dizziness, cough, dyspnea, diarrhea, nausea, fatigue, and peripheral edema. Serious adverse reactions occurring at a higher frequency (≥2% difference) in patients ≥65 years of age included pneumonia.
Clinical studies of DARZALEX FASPRO as part of a combination therapy did not include sufficient numbers of patients aged 65 and older to determine whether they respond differently from younger patients.
11 Description
Daratumumab is an immunoglobulin G1 kappa (IgG1κ) human monoclonal antibody that binds to the CD38 antigen. Daratumumab is produced in Chinese Hamster Ovary (CHO) cells using recombinant DNA technology. The molecular weight of daratumumab is approximately 148 kDa.
Hyaluronidase (recombinant human) is an endoglycosidase used to increase the dispersion and absorption of co-administered drugs when administered subcutaneously. It is a glycosylated single-chain protein produced by Chinese Hamster Ovary cells containing a DNA plasmid encoding for a soluble fragment of human hyaluronidase (PH20). Hyaluronidase (recombinant human) has a molecular weight of approximately 61 kD.
DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) injection is a sterile, preservative-free, colorless to yellow, and clear to opalescent solution supplied in a single-dose vial for subcutaneous administration.
Each DARZALEX FASPRO 15 mL single-dose vial contains 1,800 mg of daratumumab and 30,000 units of hyaluronidase , L-histidine (4.9 mg), L-histidine hydrochloride monohydrate (18.4 mg), L-methionine (13.5 mg), polysorbate 20 (6 mg), sorbitol (735.1 mg), and Water for Injection, USP.
12.1 Mechanism Of Action
CD38 is a transmembrane glycoprotein (48 kDa) expressed on the surface of hematopoietic cells, including multiple myeloma and other cell types and tissues and has multiple functions, such as receptor mediated adhesion, signaling, and modulation of cyclase and hydrolase activity. Daratumumab is an IgG1κ human monoclonal antibody (mAb) that binds to CD38 and inhibits the growth of CD38 expressing tumor cells by inducing apoptosis directly through Fc mediated cross linking as well as by immune-mediated tumor cell lysis through complement dependent cytotoxicity (CDC), antibody dependent cell mediated cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). A subset of myeloid derived suppressor cells (CD38+MDSCs), regulatory T cells (CD38+Tregs) and B cells (CD38+Bregs) are decreased by daratumumab.
Hyaluronan is a polysaccharide found in the extracellular matrix of the subcutaneous tissue. It is depolymerized by the naturally occurring enzyme hyaluronidase. Unlike the stable structural components of the interstitial matrix, hyaluronan has a half-life of approximately 0.5 days. Hyaluronidase increases permeability of the subcutaneous tissue by depolymerizing hyaluronan. In the doses administered, hyaluronidase in DARZALEX FASPRO acts locally. The effects of hyaluronidase are reversible and permeability of the subcutaneous tissue is restored within 24 to 48 hours.
12.2 Pharmacodynamics
NK cells express CD38 and are susceptible to daratumumab mediated cell lysis. Decreases in absolute counts and percentages of total NK cells (CD16+CD56+) and activated (CD16+CD56dim) NK cells in peripheral whole blood and bone marrow were observed with DARZALEX FASPRO treatment.
12.3 Pharmacokinetics
Following the administration of the recommended dose of DARZALEX FASPRO 1,800 mg/30,000 units (1,800 mg daratumumab and 30,000 units hyaluronidase) subcutaneously once weekly for 8 weeks, the mean ± standard deviation (SD) maximum trough concentrations (Ctrough following the 8th dose) were 593±306 µg/mL compared to 522±226 µg/mL for daratumumab 16 mg/kg administered intravenously, with a geometric mean ratio of 108% (90% CI: 96, 122). The estimated median daratumumab area under the concentration-time curves (AUC0–7 days) and daratumumab peak concentration (Cmax) following the 8th dose were comparable between DARZALEX FASPRO and intravenous daratumumab (4017 µg/mL∙day vs. 4,019 µg/mL∙day for AUC0–7 days and 592 µg/mL vs. 688 µg/mL for Cmax).
Following the recommended dose of DARZALEX FASPRO 1,800 mg/30,000 units, Cmax increased 4.8-fold and AUC0–7 days increased 5.4-fold from the 1st dose to the 8th dose.
13.1 Carcinogenesis, Mutagenesis, Impairment Of Fertility
No carcinogenicity or genotoxicity studies have been conducted with daratumumab. No animal studies have been performed to evaluate the potential effects of daratumumab on reproduction or development, or to determine potential effects on fertility in males or females.
No carcinogenicity, genotoxicity, or fertility studies were conducted for recombinant human hyaluronidase. There were no effects on reproductive tissues and function and no systemic exposure of hyaluronidase in monkeys given 22,000 U/kg/week subcutaneously (12 times higher than the human dose) for 39 weeks. As hyaluronidase is a recombinant form of the endogenous human hyaluronidase, no carcinogenicity, mutagenesis, or effects on fertility are expected.
15 References
- Chapuy, CI, RT Nicholson, MD Aguad, et al., 2015, Resolving the daratumumab interference with blood compatibility testing, Transfusion, 55:1545–1554 (accessible at http://onlinelibrary.wiley.com/doi/10.1111/trf.13069/epdf).
16 How Supplied/Storage And Handling
DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) injection is a sterile, preservative-free, colorless to yellow, and clear to opalescent solution for subcutaneous use supplied as individually packaged single-dose vials providing 1,800 mg of daratumumab and 30,000 units of hyaluronidase per 15 mL (NDC 57894-503-01).
Storage And Handling
Store DARZALEX FASPRO vials in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light.
Do not freeze or shake.
17 Patient Counseling Information
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Spl Patient Package Insert
This Patient Information has been approved by the U.S. Food and Drug Administration. | Issued: 05/2020 | ||||
PATIENT INFORMATION DARZALEX (Dar'-zah-lex) FASPRO™ (Fas-pro) (daratumumab and hyaluronidase-fihj) injection, for subcutaneous use | |||||
DARZALEX FASPRO may be used with other medicines called lenalidomide and dexamethasone. You should also read the Medication Guide that comes with lenalidomide if you use DARZALEX FASPRO with lenalidomide. You can ask your healthcare provider or pharmacist for information about dexamethasone. What is DARZALEX FASPRO? DARZALEX FASPRO is a prescription medicine used to treat adult patients with multiple myeloma:
| |||||
Do not receive DARZALEX FASPRO if you have a history of a severe allergic reaction to daratumumab or any of the ingredients in DARZALEX FASPRO. See the end of this leaflet for a complete list of ingredients in DARZALEX FASPRO. | |||||
Before you receive DARZALEX FASPRO, tell your healthcare provider about all of your medical conditions, including if you:
| |||||
How will I receive DARZALEX FASPRO?
| |||||
What are the possible side effects of DARZALEX FASPRO? DARZALEX FASPRO may cause serious reactions, including:
| |||||
|
|
| |||
The most common side effects of DARZALEX FASPRO used in combination therapy include: | |||||
|
|
| |||
These are not all the possible side effects of DARZALEX FASPRO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. | |||||
General information about the safe and effective use of DARZALEX FASPRO. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or healthcare provider for information about DARZALEX FASPRO that is written for health professionals. | |||||
What are the ingredients in DARZALEX FASPRO? Active ingredient: daratumumab and hyaluronidase-fihj Inactive ingredients: L-histidine, L-histidine hydrochloride monohydrate, L-methionine, polysorbate 20, sorbitol, water for injection. Manufactured by: Janssen Biotech, Inc., Horsham, PA 19044 U.S. License Number 1864 For more information, call 1-800-526-7736 or go to www.DARZALEXFASPRO.com. |
Principal Display Panel - 15 Ml Vial Box
NDC 57894-503-01
DARZALEX Faspro™
(daratumumab and
hyaluronidase-fihj)
Injection
1,800 mg and
30,000 Units/15 mL
(120 mg and 2,000 Units/mL)
For Subcutaneous Use Only
Administer subcutaneous
injection over 3 to 5 minutes.
Rx only
One 15 mL Vial
Single-dose vial.
Discard unused portion.
janssen
* Please review the disclaimer below.